Riskpilot← Back to searchSign inGet full accessCelemiab Systems Aktiebolag
ABActiveOrg 5565624003Nordenskiöldsgatan 8Other education n.e.c. · NACE 8559Est. 19980 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK 4,6M
+31% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK 4,6M | +31% |
| Total assets | SEK 5,1M | +2% |
| Equity | SEK 5,1M | +2% |
| Employees | 0 | — |
Legal name
Celemiab Systems Aktiebolag
Org number
5565624003
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
11 november 1998
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva produktion, marknadsföring och försäljning av läromedel och därmed förenlig verksamhet.
Address
Nordenskiöldsgatan 8
Email
kjell.lindqvist@celemi.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | — | — | — | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| Net financials | — | — | — | — | — |
| Profit before tax | −7 500 | 0 | 0 | 3 500 | 4 600 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 500 | 0 | 0 | 3 500 | 4 600 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 481 | 1 481 | 1 481 | 4 981 | 5 081 |
| Equity | 1 481 | 1 481 | 1 481 | 4 981 | 5 081 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | — | — | — | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
90.5%
This company
18.4%
Market median
+392% vs market
20202024
Net profit margin
460000000.0%
This company
8.1%
Market median
+5679012246% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AL Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
BM Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Celemi Holding AB
Celemiab Systems Aktiebolag Board members of Celemiab Systems Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Birgitta Maria Danckler | Chief Auditor | 0 companies |
| Ann Linnéa E Rickard Nilsson | Chief Auditor | 0 companies |
| Jan Nils Bertil Johansson | Deputy Board Member | 0 companies |
| Kjell Åke Lindkvist | Board of Directors | 0 companies |